REAFERON (ALPHA(2)-INTERFERON) INTRODUCTI ON IN THE TREATMENT OF CHRONIC MYELOID-LEUKEMIA

Authors
ABDULKADYROV KM MOISEEV SI SCHERBAKOVA YG BALASHOVA VA GLAZANOVA TV RUKAVITSYN OA MARTYNKEVICH IS GRITSAEV SV BLINOV MN
Citation
Km. Abdulkadyrov et al., REAFERON (ALPHA(2)-INTERFERON) INTRODUCTI ON IN THE TREATMENT OF CHRONIC MYELOID-LEUKEMIA, Terapevticeskij arhiv, 67(6), 1995, pp. 59-63
Citations number
15
Categorie Soggetti
Medicine, General & Internal
Journal title
Terapevticeskij arhiv → ACNP
ISSN journal
00403660
Volume
67
Issue
6
Year of publication
1995
Pages
59 - 63
Database
ISI
SICI code
0040-3660(1995)67:6<59:R(IOIT>2.0.ZU;2-P
Abstract
The effectiveness of domestic alpha(2)-interferon preparation reaferon was studied in vivo and in vitro for eradication of pathological hemo poietic clone in chronic myeloid leukemia. Reaferon administration for 1-30 months produced cytogenetic remission in 36% of the patients. Re aferon is indicated in chronic myeloid leukemia without splenomegaly. In the disease progression reaferon is uneffective. Mechanism of reafe ron therapeutic action comprises three components: a direct antiprolif erative effect on hemopoietic precursor cells, activation of cellular immunity, an effect on stem cell microenviroment.